Company profile
UK company 12856905, incorporated on 3 September 2020.
Kargenera Limited is a UK company with status active founded in 2020 based in South East England.
Company number 12856905
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
Kargenera develops peptide-based DNA medical therapies for treating cancer.
The company is designed to commercialise peptide based DNA therapy to activate natural killer cells as a cancer immunotherapy. We are currently agreeing terms with University for this. The company is supported by 3 patents, We have a CEO and founder at present but we have not yet secured funding.
None at present.
1 May 2024 to 30 Apr 2025
We are developing a new product to treat cancers of high unmet need. The goal is to make an RNA therapeutic cancer vaccine that targets a part of the immune system called natural killer cells. Natural killer cells have been demonstrated to have anti-cancer properties, and our vaccine approach will boost the natural killer cell response to cancers expressi...
